Managing the drug discovery process: how to make it more efficient and cost-effective

Free download. Book file PDF easily for everyone and every device. You can download and read online Managing the drug discovery process: how to make it more efficient and cost-effective file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with Managing the drug discovery process: how to make it more efficient and cost-effective book. Happy reading Managing the drug discovery process: how to make it more efficient and cost-effective Bookeveryone. Download file Free Book PDF Managing the drug discovery process: how to make it more efficient and cost-effective at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF Managing the drug discovery process: how to make it more efficient and cost-effective Pocket Guide.

Also, consolidated packaging and labelling, consolidated shipments, and a new inventory system helped the company better manage supplies. Kanban also applies to maintaining drug inventory. When pharma companies were riding high on the billion dollar sales of blockbuster drugs, the expense of keeping inventory levels high inventories posed little concern.

But pharma companies can make better choices about which products they stock at high levels.

Media Types

When it comes to keeping inventory levels high, there is a difference between expensive life-saving drugs and a low-demand, low-margin products, Pharmaceutical Executive explains. Pharma companies can make smarter decisions about which drugs they keep on hand, and in what quantities.

Inventory levels of lower margin products can be kept at a minimum, which helps lower drug manufacturing costs. Pressure on pharmaceutical companies to become more productive and more efficient has never been greater.

The Importance of Liquid Handling Quality Assurance Through the Drug Discovery Process

Besides the looming patent expirations facing blockbuster drugs, drug pipelines that once held promise of delivering new blockbusters have steadily dried up. Meanwhile, insurers, health care providers, and patients have become more vocal in calling for pharma companies to keep rising drug prices in check. Productivity and pricing concerns can be alleviated by making the drug discovery and development process more efficient.


  • The Race Beat: The Press, the Civil Rights Struggle, and the Awakening of a Nation;
  • 40 Days of Purity for Girls;
  • Credit Derivatives Handbook - Volume 1.
  • Real-world data can help make better drugs and do it faster - STAT.
  • Emerging Drug Discovery Alliance Models.

Primary among these is the dwindling number of people with adequate retirement health benefits. Many employers are reducing their retirement plans and others are opting for defined contribution plans rather than defined benefit plans.

Kanban in Drug Discovery and Development

Some of them are also eliminating their retiree health care coverage programs. A consequence of this will be an increase in the number of people who reach retirement with little or no health insurance, including no drug benefit. Finally, the rising numbers of on-line pharmacies Canadian and elsewhere will add weight to the government and private sector efforts to reduce pharmaceutical sales.

The studies given the most attention are based on empirical work that attempts to estimate the resource costs of new drug development. Review of drug development cost studies. Finally, each of the reviewed studies is limited to self-originated NCEs. In Hansen reported on a sample of NCEs first tested in humans between and and obtained from 14 pharmaceutical firms. However, he included licensed NCEs in his estimate, which would tend to give a lower average cost than including only self-originated NCEs.

Public Citizen a national consumer group has raised numerous concerns about the DiMasi study. Virtually all economists would argue there is nothing theoretical about the cost of capital. Public Citizen raised similar concerns about the DiMasi study, but did not offer any additional analysis. DiMasi and others have repudiated their assessment, arguing that the aim of the study was to estimate resource costs, not effective cost to firms. Finally, they characterize exclusion of the cost of capital by Public Citizen as a major methodological flaw.

Summary of cost studies. We also should note that improvements in the drug development process would yield significant improvements in this picture. He also reports that improving success rates from the current Any adverse disturbance to the scientific research, regulation or use of pharmaceuticals will have detrimental effects on social value.

Figure 4 also shows that opportunities to improve societal benefits can come from multiple pathways, including a more efficient development process, a favorable regulatory environment, and improved use of drugs. Value of new drugs. This is a germane question, as attempts to reduce pharmaceutical expenditure generally focus on constraining the use of newer drugs.

He attributed the increase to the use of new medical technologies including drugs and suggested that there was a positive effect on life expectancy and the health status of the elderly. For example, use of antibiotics to prevent deaths from infections can cause people to live longer and hence to die from heart disease and cancer, which typically entail even greater costs.

This is the dilemma and the lesson; the value of pharmaceutical innovations often cannot be captured in conventional accounting calculations. Value and cost summary. Pharmaceuticals create value in terms of reduced non-drug healthcare expenditure as well as contributing to improvements in patient quality-of-life that often defy quantification. In addressing this issue, we assume that few would want to turn back the medical care clock to the time when mercurial diuretics and sulfonamides were standards of care.

The task of discovering and developing novel NCEs is unusual, if not unique, among business enterprises because it is financed almost entirely by the private sector although many regard the results, such as improved health, as a public benefit. The private sector status of pharmaceutical research means that the industry must generate sufficient income and make a sufficient return on investment to cover the cost of developing the next generation of NCEs.

Since health care is viewed differently than consumer products, the drug development activities of the pharmaceutical industry are examined closely and subjected to a higher standard of performance than other private sector businesses. There is an expectation that pharmaceuticals will be generally affordable, and that industry resources will be used to develop needed therapies.

This situation begs the question: what is the most efficient means of moving NCEs from the laboratory to the consumer? Is it the current model dominated by large pharmaceutical companies engaged in the complete range of activities from research to marketing?

Kanban in Drug Discovery and Development - HYPER38

Or has research become so specialized that it is more efficient to foster the growth of smaller, more specialized research-only companies, as some have suggested? Regardless of the answer, it is clear that drug development will remain in the private sector rather than being nationalized or funded by the government. However, government is assuming a larger role in paying for innovative new drugs and therefore has a stake in the efficiency of the development process. Traditionally, the cost of drug therapy has been principally the concern of patients, because lower efficiency translated into higher prices for them.

He argues that as government pays more of the cost of pharmaceuticals, they see innovative new products as a threat, whereas patients are more likely to have a positive attitude towards innovation, especially where the drug benefit is subsidized. The public desire for new therapies, their increasing cost, and the increased role of government as a payer for innovative new drugs, all converge on the question of the cost of new drug development and argue for an efficient use of resources. The issue of drug development cost is therefore woven into many aspects of health care policy.

Factual information cited in this paper is taken directly or indirectly from one or more of the sources cited here. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development.


  • Japanese Art Selections from the Mary and Jackson Burke Collection.
  • The Last Best Hope: Restoring Conservatism and Americas Promise.
  • Real-world data can help make better drugs and do it faster.
  • Download Now.
  • Managing the Drug Discovery Process!
  • Tweak It: Make What Matters to You Happen Every Day.
  • Rights and permissions.

Nature Reviews Drug Discovery , The horizontal integration of CDMO and CRO capabilities enables a shortened make-test cycle where a trial sponsor can integrate drug product manufacturing within the clinical program. Shortened Cycle Times Using a fit-for-phase manufacturing strategy, make-test cycles can be as short as days rather than weeks or months.

In a day cycle time, for example, products are manufactured in real time at the precise dose or composition required, immediately before dosing the volunteers or patients in a clinical trial. The drug product can then be fine-tuned in response to the clinical safety, pharmacokinetic PK and pharmacodynamic PD data emerging from within the study. This process reduces chemistry, manufacturing and controls CMC investments, conserves drug substance and allows human data to drive key decisions Figure 4.

Formulation Design Space Flexibility It is difficult to predict the quantitative levels of critical-to-performance components in a drug formulation that enables the program to achieve the desired clinical endpoints. Traditionally, development teams rely on surrogate, non-clinical, in vitro or in silico tools to determine that information before beginning a study, but that means accepting a certain level of risk.

In an integrated approach, inclusion of a formulation design space enables realtime flexibility to adjust the quantitative composition of the formulation based on emerging clinical data Figure 5. Coupled with real-time manufacturing, it is possible to assess multiple formulation technologies and drug products in a clinical trial without having to secure regulatory or institutional review board IRB approval every time the dose or formulation is adjusted.

The drug company efficiently manufactures optimized drug products and moves through early development, adapting quickly to any emerging PK, PD or safety data in FIH and dose escalation trials. Accelerate Molecules From First-in-Human to Proof-of-Concept For an FIH study, a simple fit-for-phase drug product strategy is typically used to provide dose flexibility with minimal upfront investments.

However, this does not address the risks of poor oral bioavailability due to challenging drug chemistry, or the need to identify a solid oral dosage form for POC. Through the use of real-time adaptive manufacturing, it is possible to alter dose levels, formulations and drug product types within the clinical trial, without amending the protocol, and then maintain a seamless supply of the lead drug product as the drug candidate progresses into downstream patient trials.

What are real-world data?
admin